

Pfizer New Zealand Limited Level 1, Suite 1.4, Building B, 8 Nugent Street, Grafton, Auckland 1023 PO Box 3998, Shortland Street, Auckland, New Zealand 1140 Tel: 09 354 3065 Fax: 09 374 7630

Pfizer New Zealand Limited

18 August 2020

Dear Healthcare Professional,

NOTIFICATION OF TEMPORARY ALTERNATIVE PRODUCT SUPPLY

Pfizer New Zealand (Pfizer) wishes to advise that **NORIMIN[™] 28 Day tablets** is out of stock. The Australian **BREVINOR[®] 28 Day tablets** have been granted provisional registration under section 23 of the Medicines Act 1981 as a temporary alternative for patients in New Zealand.

Status	Presentation	Registration	Pharmacode [®]	Pack Size	Stock Status
OUT OF STOCK	NORIMIN [™] 28 Day (0.5mg norethisterone / 0.035mg ethinylestradiol)	TT50-5909	410691	3 blisters x 28 tablets (84)	Current
TEMPORARY ALTERNATIVE (Australian product)	BREVINOR [®] 28 Day (0.5mg norethisterone / 0.035mg ethinylestradiol)	TT50-10759	2598035	4 blisters x 28 tablets (112)	Available 1 Sep 2020

All pharmacological aspects of the two products are identical and dosing instructions are the same. There are differences in carton labeling and patient information documents. This information is listed in the table below:

Category	NEW ZEALAND product NORIMIN [™] 28 Day	AUSTRALIAN product BREVINOR [®] 28 Day	
Pack Size	3 blister strips x 28 tablets	4 blister strips x 28 tablets	
Active tablet appearance	Blue	Blue	
Placebo tablet appearance	Orange	Orange	
Sponsor contact details	Pfizer New Zealand Limited	Pfizer Australia Pty Ltd	
	Auckland, New Zealand	Sydney, NSW, Australia	
Medical Information	New Zealand: 0800 736 363	Australia: 1800 675 229	
	medicalaffairs.anz@pfizer.com	medicalaffairs.anz@pfizer.com	
Poison contact details	National Poisons Centre	Poisons Information Centre (telephone	
	(telephone 0800 764 766)	13 11 26)	

Please refer to the Brevinor[®] 28 Day (Australian Stock) Data Sheet and Consumer Medicines Information document in www.medsafe.govt.nz for the complete product information.

We thank you in advance for your understanding and apologise for any inconvenience caused to you and your patients. For any medical or stock queries please contact Pfizer on 0800 736 363.

Please report any suspected adverse events via email to Pfizer Drug Safety at AUS.AEReporting@pfizer.com. Alternatively, suspected adverse events may be reported to the Centre for Adverse Reactions Monitoring (CARM) in Dunedin online at https://nzphvc.otago.ac.nz/reporting or by email to carmnz@otago.ac.nz

Yours faithfully,

Dr. Charanjeet Singh Assoc. Medical Director, Internal Medicine Pfizer New Zealand